VAUGHAN, ON and HEIDELBERG, Germany, July 7, 2022 — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated …
NOV03 Met Primary Endpoints for Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction in Both Phase 3 Trials VAUGHAN, ON and …
NOV03 Met Both Primary Endpoints for Signs and Symptoms of Dry Eye Disease VAUGHAN, ON and LAVAL, QC and HEIDELBERG, Germany, April 25, 2022 — …
DSP-0390, an investigational new agent developed by Cambridge, Massachusetts-based Sumitomo Dainippon Pharma Oncology, is an inhibitor of emopamil-binding protein (EBP), a molecule in cholesterol biosynthesis. …